CD38 and B-cell chronic lymphocytic leukemia: Very recently, entospletinib demonstrated promising clinical activity in patients with relapsed or refractory CLL.[18] Given the association between SYK and CD38 in lymphoid cells, we aimed to determine whether SYK is involved in CD38 signaling in CLL cells and may represent a potential target to prevent CD38-mediated CLL cell survival, and migration.